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doi:10.1016/j.ejvs.2010.08.023Abstract Objectives: Modulation of abdominal aortic aneurysm (AAA) expansion by HMG-CoA
reductase inhibitors (statins) might be linked to reducing IL-6 and MMP-9, which may be conse-
quent on reducing plasma cholesterol. Ezetimibe is a novel cholesterol absorption inhibitor
used in combination with statins. This pilot study compared the biological effects of ezetimibe
combination therapy with simvastatin alone on parameters relevant to aneurysm expansion
including cytokines and proteolytic enzymes.
Design: Randomised placebo-controlled double-blind trial.
Materials & Methods: Eighteen patients scheduled for elective open AAA repair were rando-
mised to simvastatin 40 mg plus ezetimibe 10 mg (n Z 9), or simvastatin 40 mg plus placebo
(n Z 9), for 32.5 days (IQR 28e50.5) until the day of surgery. Total concentrations of TNF-a,
IL-1b, IL-6, IL-8, IL-10, MMPs-1, -2, -3, -8, -9, -12, -13, TIMP-1 and -2 were measured in plasma,
aortic wall homogenates and tissue culture explants.
Results: Two patients in the placebo arm did not undergo open repair precluding aortic
samples. Ezetimibe was associated with a significant reduction in aortic wall MMP-9
(p Z 0.02) and aortic wall IL-6 (p Z 0.02), associated with a reduction in plasma lipids.
Conclusions: These results suggest that ezetimibe combination therapy reduces aortic wall
proteolysis and inflammation, key processes that drive AAA expansion. A larger RCT is justified
focussing on aneurysm growth rates in small AAA.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.sed Controlled Trial Number (ISRCTN) is not recorded for this study as it was commenced just prior to
by the International Committee of Medical Journal Editors. However, it has been registered with the
ase (Central Office of Research and Ethics Committee) and National Health Service Databases through
and Development Department.
08 725 3205; fax: þ44 208 725 3495.
oo.co.uk (J.A. Dawson).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Ezetimibe Reduces AAA Inflammation and Proteolysis 29Introduction
Abdominal aortic aneurysms (AAA) cause 10 000 deaths a year
in England alone, comprising the third commonest cause of
suddendeathaftermyocardial infarctionandcerebrovascular
accidents.1 It is anticipated that screening programmes will
reduce the number of patients presenting in the future with
previously undiagnosed, ruptured aneurysms. Conversely,
screeningwill lead toadramatic rise in thenumberofpatients
with newly diagnosed small aneurysms, for which there is
currently no treatment. There has therefore never been
a more pressing need for a pharmacological solution to
aneurysm expansion. Forty years of research have failed to
unequivocally demonstrate a single agent with which to halt
aneurysm expansion,2,3 but promising results suggest that
HMG-CoA reductase inhibitors (statins) may reduce aneurysm
growth, both in animal models and human cohort studies.
One randomised trial comparing simvastatin to placebo
in aneurysm patients was curtailed due to the simultaneous
recommendation that all AAA patients should be medicated
with statins, rendering the placebo arm of the trial
contentious.4 The definitive place of statins in aneurysm
retardation therefore remains unanswered, but continued
research into this area is challenged by the ubiquitous use
of statins. Although cholesterol-independent ‘pleotropic
effects’ have been proposed to explain the mechanism of
action of statins, there is evidence to suggest that their
benefits are principally due to lipid-modification. In addi-
tion, epidemiological studies suggest that hyperlipidaemia
plays a role in aneurysm development.5
The hypothesis of the present study was that additional
advantages might be gained by aggressively reducing
cholesterol with a combination of the lipid-lowering agents
ezetimibe, a cholesterol absorption inhibitor, and simvas-
tatin. When combined with simvastatin ezetimibe has
synergistic effects on cholesterol reduction,6 and it was
hypothesised that the biological effects of combination
therapy would be greater than that of simvastatin alone on
parameters relevant to aneurysm expansion such as matrix
metalloproteinases (MMPs), tissue inhibitors of matrix
metalloproteinases (TIMPS) and cytokines.
Materials and Methods
Participants
Patients with large AAA scheduled for elective open aneu-
rysm surgery were eligible. Exclusion criteria included
emergency, urgent or endovascular repair, contra-indica-
tions to trial drugs, significant concomitant diseases,
malignancy and inflammatory disorders including inflam-
matory AAA.
Interventions
Patients were subject to a two-week lead-in period of sim-
vastatin therapy, 40mg daily prior to randomisation, in order
to limit confounding factors associated with pre-existing
statins or doses taken prior to recruitment. Existing choles-
terol lowering agents were stopped during this period.
Patients were then randomised to simvastatin 40 mg plusezetimibe 10 mg or simvastatin 40 mg plus placebo. All study
drugs were provided in identical, sealed, sequentially
numbered bottles (Merck Sharpe and Dohme, Hoddesdon,
UK). Trial medications were delivered to and dispensed by
the hospital pharmacy and each patient received two bottles
marked ‘simvastatin 40mg’ and ‘ezetimibe/placebo’with an
allocation number. Simvastatin tablets were standard open-
label. Ezetimibe and placebo tablets were identical in size,
shape and colour. Patients took both tablets together every
evening leading up to their operation, their last dose taken
the night before surgery. Compliance was monitored by
tablet counts. Following the trial, patients continued a sta-
tin, as is normal clinical practice.
Objectives
The hypothesis tested was that enhanced cholesterol
lowering with a combination of ezetimibe and simvastatin
would produce greater biological changes in the aortic wall
conducive to retarding the aneurysmal process than sim-
vastatin alone. Inflammatory cytokine and proteolytic
enzyme protein concentrations were measured in the
aneurysm wall as surrogate markers of aneurysm activity.
Outcomes
Primary outcome measures were aortic wall concentrations
of inflammatory cytokines (tumour necrosis factor-a (TNF-
a), interleukin (IL)-1b, IL-6, IL-8, IL-10) and proteolytic
enzymes (MMP-1, -2, -3, -8, -9, -12, -13, TIMP-1, TIMP-2).
Secondary outcome measures included plasma concentra-
tions of the same cytokines and proteolytic enzymes,
C-reactive protein (CRP) and plasma lipids.
Sample procurement
Following the two-week lead-in period, blood samples for
secondary outcome measures were obtained at three time
points during the study; on the day of trial drug
commencement (‘start’), a mid-trial sample at 15 days (IQR
15e24) (‘mid’), and on the day of surgery at 32.5 days (IQR
28e50.5) (‘end’). 20 ml of peripheral blood was obtained
from the antecubital fossa and centrifuged for 10 min at
3000 rpm. Plasma was stored in aliquots at 80 C prior to
batch analysis. At open AAA repair a standardised
5 cm  2 cm full-thickness aneurysm biopsy was harvested
from the anterior sac 2 cm distal to the left renal vein. This
position has previously been considered a zone of proximal
transition where degenerative aneurysmal activity is likely
to be most aggressive.7 The biopsy was then immediately
transported to the laboratory at room temperature in
sterile tissue culture medium (Dulbecco’s Modified Eagle
Medium GIBCO D-MEM High Glucose, Invitrogen).
Laboratory methods
The biopsy was weighed and divided into 2 equal parts. One
part was homogenised and subject to dialysis to extract MMPs
and TIMPs.8 The other part was divided into equal sized pieces
and established in tissue culture (D-MEM, 37 C, 4% CO2) to
determine cytokine concentrations.9 The culturemediumwas
Figure 1 Consolidated Standards of Reporting Trials
(CONSORT) flow diagram.
30 J.A. Dawson et al.replaced every 48 h and the collected medium centrifuged to
remove debris. Both tissue homogenates and tissue culture
supernatants were frozen in aliquots at 80 C until analysed
for MMPs and cytokines respectively. Plasma, homogenates
and culture media were analysed in duplicate using a Fluo-
rokine MAP assay (R&D Systems, Inc, Minneapolis, US) and
a Luminex 100 analyser (Luminex Corp, USA) to determine
MMP (pro-, active and TIMP-1-complexed forms), TIMP and
cytokine protein concentrations. Lipids were determined by
standard hospital assay.
Sample size
Sample size calculation for this study was determined
pragmatically as the hypothesis to be tested had little
laboratory data on which to base a sample size calculation.
We aimed to recruit 20 patients to each arm. This experi-
ment was regarded as a pilot study to allow further rand-
omised trials with aneurysm expansion as an end point.
Randomisation
A computer generated randomisation list was drawn up and
kept off-site by a third party (Merck Sharpe and Dohme,
Hoddesdon, UK). On recruitment patients were allocated
the next available number according to the allocation
sequence. The sequence was concealed from the investi-
gators until recruitment, sample collection, laboratory
experiments, and data analyses were complete.
Blinding
Participants, recruiters, pharmacists and those collecting
and analysing the data were all blinded to the group
assignment due to identical bottles, tablets, and adminis-
tration of drugs. Patients administered the treatment at
home and did not meet other participants.
Statistical methods
Categorical variables were compared by a Chi-square test.
Continuous data is presented as median (IQR) and analysed
using Mann Whitney paired test. Analysis of secondary
outcome measures between the two groups was performed
using two-way analysis of variance (ANOVA). Statistical
significance was defined by a P-value of less than 0.05.
Statistical analysis was performed using Prism 4.0 software
(GraphPad Software, Inc., San Diego, CA).
Ethics
The study was approved by the Local Research Ethics
Committee through the Central Office for Research Ethics
Committees (COREC) and patients gave written informed
consent.
Results
Over a period of 22 months a total of 24 consecutive
patients with large aneurysms scheduled for elective open
aneurysm repair were assessed for eligibility to enter thetrial (Fig. 1). Fewer patients were recruited than expected
largely due to the increased utilisation of endovascular
repair during the period of the trial. The delay required
between randomisation and surgery inevitably excluded
some patients who needed urgent repair. Four patients
were excluded due to drug interactions (n Z 2), travelling
abroad prior to surgery (n Z 1) and refusal to participate
(n Z 1). Twenty patients were recruited and entered the
two-week lead-in period, during which time one patient
withdrew from the trial without giving a reason and another
was withdrawn as their planned repair modality was revised
to endovascular repair (EVAR). After two weeks eighteen
patients were randomised, nine into each group. All
patients completed their allocated treatment with no los-
ses to follow-up. Patients were well matched for baseline
demographics (Table 1). Two patients in the placebo arm
did not undergo open surgery due to deteriorating respi-
ratory function, precluding an aortic biopsy and were
therefore excluded from analysis. One underwent EVAR,
and one was anatomically unsuitable for EVAR. Therefore
9/9 patients in the ezetimibe group and 7/9 patients in the
placebo group underwent intention-to-treat analysis for the
primary outcome measure. Nine out of nine patients in
each group underwent intention-to-treat analysis for the
secondary outcome measures.
The median trial duration was 36 days (IQR 28.5e50.5)
and 30 days (28e60) for the ezetimibe and placebo groups
respectively (p Z 0.73), with no significant difference in
lead-in period or mid-trial duration (Table 1). There were
no adverse drug events in either group. Regarding primary
Table 1 Patient Demographics (age (years), AAA diameter (mm) and trial duration (days) as median (IQR)).
ezetimibe (n Z 9) placebo (n Z 9) P-value
Age 72 (65e77) 70 (65e76) 1.00
AAA diameter 56 (53e66) 59 (53e63) 0.80
Sex (male) 8 (89%) 8 (89%) 1.00
Hypertension 5 (56%) 8 (89%) 0.29
Ischaemic heart disease 3 (33%) 2 (22%) 1.00
Cerebrovascular disease 2 (22%) 0 (0%) 0.47
Chronic renal failure 1 (11%) 1 (11%) 1.00
Diabetes 1 (11%) 1 (11%) 1.00
Smoker 7 (78%) 9 (100%) 0.47
Aspirin 8 (89%) 5 (56%) 0.29
Lead-in period 14 (14e14) 14 (14e15) 0.73
Mid-trial duration 15 (14e22) 15 (14e34) 0.93
Total trial duration 36 (29e51) 30 (28e60) 0.73
Ezetimibe Reduces AAA Inflammation and Proteolysis 31outcome measures, aortic wall MMP-9 and IL-6 concentra-
tions (Figs. 2 and 3) were found to be significantly lower in
the ezetimibe/simvastatin group compared to simvastatin
monotherapy (Table 2). MMP-1, -3, -13, TIMP-1,-2 and TNF-
a, IL-1b and IL-10 were below the recordable levels of the
assay. MMP-2 was detectible with median values just within
the lower range of the assay (<25.4 pg/ml). There were no
differences in plasma variables between groups (Table 3,
MMP-8, MMP-12, MMP-13 were below the recordable levels
of the assay). Plasma total cholesterol and non-HDL
cholesterol concentrations were significantly lower with
ezetimibe combination therapy with non-significant
reductions in LDL-C and TG.
Discussion
The present study has demonstrated significant reductions
in aortic wall MMP-9 and IL-6 concentrations associated
with ezetimibe and simvastatin combination therapy,Figure 2 Box and whisker plot representing aortic wall MMP-
9 in the ezetimibe and placebo groups. Whiskers represent
data within 1.5 IQR of the lower and upper quartiles. Mild
outliers are represented by dots.compared to simvastatin alone. This was accompanied by
a reduction in plasma total cholesterol and non-HDL
concentrations. Although there was a non-significant
reduction in aneurysm wall MMP-2 within the ezetimibe
group, these results must be viewed with caution, as some
levels were so low as to fall outside the working range of
the assay. Our results mirror earlier studies in which statin
use was associated with a reduction in aneurysm wall MMP-
9 and IL-6, but not MMP-2.4,10 MMP-2 has been associated
with small aneurysms, whereas MMP-9 is implicated in
expansion and rupture, and it is therefore not surprising
that this distribution of MMPs is found in end-stage disease.
The inflammatory and proteolytic effects of IL-6 and MMP-9
are strongly implicated in the molecular basis of aneurysm
pathogenesis.10,11 In vitro studies have demonstrated that
statins exhibit both anti-inflammatory and anti-proteolytic
properties, identifying them as potential agents with which
to combat biological redundancy, a phenomenon that has
hampered previous pharmacological approaches to aneu-
rysm expansion. The anti-inflammatory effects of statinsFigure 3 Box and whisker plot representing aortic wall
interleukin-6 in the ezetimibe and placebo groups. Whiskers
represent data within 1.5 IQR of the lower and upper quartiles.
Mild outliers are represented by dots.
Table 2 Primary Endpoints: Aortic Wall Cytokine & Protease Concentrations (median (IQR)).
Protein (pg/ml) Placebo Ezetimibe P-value
MMP-2 36 (28.9e45.7) 29.1 (16.8e32.6) 0.17
MMP-8 16.5 (8.7e36.4) 11.6 (7.7e17.8) 0.25
MMP-9 57.2 (38.6e67.7) 24.5 (9.9e34.7) 0.016
MMP-12 12.6 (4.1e49.4 13.0 (4.5e27.3) 1.00
IL-6 74.4 (39.6e125.3) 26.4 (22.7e39.0) 0.016
IL-8 26.8 (14.7e48.3) 12.6 (7.4e62.7) 0.41
32 J.A. Dawson et al.are legion, comparable with the powerful anti-inflamma-
tory agent indomethacin.12 These effects include modula-
tion of cytokines, chemokines, chemoattractants, T-helper
cells, CD40 signalling, nuclear transcription factor-kB,
peroxisome proliferator-activated receptors and nitric
oxide bioavailability.13e17 Some of these inflammatory
mediators regulate the expression and activation of
MMPs,15 and statins have also been shown to reduce the
activity of several MMPs, including MMP-9 in macro-
phages,18,19 monocytes,20 fibroblasts21 and vascular smooth
muscle cells.22,23
With regard to AAAs, tissue culture studies have shown
that statins reduce the expression of proteolytic enzymes
and cytokines in aortic explants, including MMP-9,
cathepsins and IL-6.10,24,25 Two animal studies using the
elastase induced aneurysm model demonstrated that statin
therapy can suppress the extent of aneurysm formation by
about 25%, and the incidence by approximately 30%.17,26
This was associated with a reduction in MMP-9 levels and
a downregulation in genes related to inflammation and
extra-cellular matrix remodelling. Despite extensive
evidence demonstrating the anti-inflammatory effects of
statins, the inflammatory cell infiltrate was unaffected,Table 3 Secondary Endpoints: Plasma Lipids, Cytokines & Prote
points between two groups utilising two-way ANOVA.
Secondary Outcome Measure Placebo
start mid end
Lipids (mmol/l)
Total cholesterol 4.3 (1.0) 3.9 (0.7) 4.0 (
LDL-C 2.4 (0.9) 1.9 (0.7) 2.0 (
HDL-C 1.2 (0.3) 1.2 (0.3) 1.2 (
Non-HDL-C 3.1 (0.9) 2.7 (0.6) 2.8 (
Triglycerides 1.9 (1.2) 1.7 (1.0_ 1.6 (
Cytokines (pg/ml)
C-reactive protein 5.5 (7.7) 5.3 (6.6) 4.4 (
TNF-a 3.7 (1.1) 3.8 (1.1) 3.7 (
IL-1b 0 (0) 0 (0) 0 (0)
IL-6 3.5 (2.2) 3.8 (3.3) 3.4 (
IL-8 8.5 (4.2) 11.5 (5.5) 7.8 (
IL-10 0.4 (0.4) 0.5 (0.5) 0.4 (
Proteases (pg/ml)
MMP-1 582 (330) 662 (401) 451 (
MMP-2 22830 (4429) 22970 (3831) 20560
MMP-3 1686 (643) 1794 (599) 1462
MMP-9 2149 (532) 2491 (578) 2255
TIMP-1 144 (49) 134 (41) 124 (
TIMP-2 106 (34) 101 (25) 103 (suggesting that statins mediate their effects by blocking
inflammatory signalling cascades.17 Similarly, other studies
have shown statin-mediated reduction in MMP-9 secretion
by neutrophils and macrophages in AAA explants is not
accompanied by a reduction in inflammatory infiltrate.25
Human cohort studies involving ultrasound surveillance
programmes have reported an almost 50% reduction in
aneurysm expansion associated with statin use.27e29 These
studies demonstrated a significant reduction in aneurysm
growth and rupture rates associated with statin
therapy.28,30 One study demonstrated a greater effect in
patients with small aneurysms, indicating that early phar-
macologic intervention may be more effective during the
initial stages of aneurysmal degeneration.28 However,
despite adjustments made for potential confounding
factors, these uncontrolled observational studies may be
subject to unrecognised bias, with these associations
simply reflecting another factor linked to statin indica-
tion.3 For this reason randomised clinical trials are essen-
tial to determine the true effect that statins have in
suppressing aneurysm growth. The only other clinical trial
prior to the present study involved randomising patients
scheduled for AAA repair to 6 weeks of simvastatin 40 mg orases. Comparison is made of mean values (SD) over the 3 time
Ezetimibe P-value
start mid end
0.7) 3.8 (0.4) 3.3 (0.6) 3.2 (0.4) 0.03
0.7) 2.0 (0.3) 1.6 (0.4) 1.5 (0.3) 0.12
0.4) 1.2 (0.4) 1.2 (0.4) 1.2 (0.4) 0.77
0.7) 2.6 (0.4) 2.2 (0.7) 2.0 (0.4) 0.04
1.1) 1.4 (0.6) 1.4 (1.0) 1.1 (0.4) 0.28
3.8) 6.2 (10.7) 5.6 (8.3) 5.1 (8.4) 0.88
0.9) 4.7 (1.6) 4.4 (1.3) 4.5 (1.7) 0.21
0.8 (2.0) 0 (0) 0.5 (1.2) 0.10
1.8) 3.2 (2.0) 3.5 (2.4) 3.5 (2.4) 0.88
5.4) 10.2 (7.0) 12.6 (5.8) 10.5 (5.8) 0.45
0.4) 0.6 (0.7) 0.6 (0.7) 0.6 (0.8) 0.42
308) 850 (830) 671 (482) 629 (542) 0.5
(3106) 24180 (3305) 23060 (1951) 20730 (2034) 0.68
(771) 2303 (1062) 2352 (1370) 1624 (862) 0.29
(690) 2602 (805) 2243 (732) 2227 (818) 0.85
48) 133 (49) 128 (60) 125 (28) 0.79
30) 111 (11) 120 (24) 97 (18) 0.49
Ezetimibe Reduces AAA Inflammation and Proteolysis 33placebo, prior to surgery. Unfortunately this study had to
be discontinued early due to ethical considerations,
following the simultaneous publication of the Heart
Protection Study, indicating that virtually all patients
suitable for inclusion to the trial should be on a statin.31
Despite only recruiting 17 patients, simvastatin was found
to significantly lower MMP-9 concentrations by 40% within
the aneurysm wall, compared to placebo.4 This study
demonstrated for the first time that statins could inhibit
MMP secretion in the aneurysm wall using therapeutic
doses. Allied in vitro experiments in the same study
demonstrated that therapeutic concentrations of simvas-
tatin decreased aortic MMP-9 and IL-6 concentrations in
tissue culture, with a preservation of arterial elastin. This
study provided a plausible biological link to the observa-
tional studies suggesting that statins retard aneurysm
expansion and led to the design of the current study.
The mechanism of action underlying the apparent ability
of statins to inhibit aneurysm expansion is undetermined.
Traditionally it was believed that statins confer their actions
solely by cholesterol lowering through the inhibition of
mevalonic acid, resulting in reduced cholesterol biosyn-
thesis.32 However blockage of this pathway also impedes the
production of other essential proteins, leading to a wide
range of cholesterol-independent, or ‘pleotropic’ effects,
including anti-inflammatory and anti-proteolytic actions.33
Many pleotropic effects have been identified and demon-
strated in rodents in whom statins have no effect on circu-
lating cholesterol levels,34,35 bringing into question the
traditional cholesterol-dependent mechanism of action of
statins.34,36 However, circulating lipoprotein concentrations
do not accurately reflect lipid biology at the endothelial cell
membrane level,15 where statins may act to improve endo-
thelial function by reducing cellular uptake of lipids.34,36e38
In addition the doses required to demonstrate pleotropic
effects in rodents are often incompatible with humans.15
Therefore the clinical significance of pleotropic actions has
been brought into doubt,39 and currently there is no direct
clinical evidence distinguishing lipid-lowering-dependent
from lipid-lowering-independent benefits of statins in
humans.15,35 As hypercholesterolaemia itself is a highly
inflammatory state36 there are considerable benefits to
reducing circulating lipids by any method.34,40 For example,
a reduction in MMPs occurs in response to dietary lipid-
lowering alone,15 and the addition of ezetimibe to simvas-
tatin has significant additional anti-inflammatory effects
compared to simvastatin monotherapy.41 Numerous epide-
miological studies have identified a link between hyper-
cholesterolaemia and the presence, risk and size of
AAA,5,42e51 with multivariate analysis suggesting that this
association is not merely secondary to concurrent athe-
rosclerosis.5,42,48e51 Our resultsmay reflect a combination of
effects, including the benefits of additional lipid-lowering by
simvastatin and ezetimibe, in combination with the pleo-
tropic actions that statins may offer.Limitations of the study
Despite recruitment challenges potentially underpowering
this study, we have demonstrated a similar magnitude
reduction in MMP-9 as previous studies, with a similarnumber of patients.31 For ethical reasons the trial was
intentionally short so that it wouldn’t impede on the
waiting time for surgery and this could lead to an under-
estimation of potential effects. Previous studies have
indicated that anti-inflammatory effects occur within 14
days of commencing simvastatin.52 In common with the
majority of research in this field, this study is limited by
the representation of a single measurement towards the
end of the pathological process, which may account for the
inability to reliably quantify several proteins both in AAA
wall and plasma. The difficulty in extracting proteins from
such tissues may also account for the lack of concordance
between plasma and aortic levels of cytokine and MMPs.
However, the primary outcome measures chosen were
aortic wall proteins as these more closely reflect the bio-
logical processes occurring within the aneurysm itself. We
have not measured aneurysm expansion, and although
based on a large body of evidence, we are relying on
surrogate markers of aneurysm activity. Although multiple
testing could account for our results, both MMP-9 and IL-6
have consistently been implicated in AAA pathophysiology
in previous studies.
Conclusion
Our findings suggest that the combination of ezetimibe and
simvastatin is a potentially powerful agent, which at ther-
apeutic levels, targets both the inflammatory and proteo-
lytic components that drive aneurysm expansion. These
results would support a larger trial evaluating the role of
combination therapy on aneurysm expansion in small
aneurysms or sac stabilisation following EVAR. Until then
the promising role of lipid-modifying drugs on aneurysm
expansion remains undetermined.
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